BenevolentAI – Augmenting human intelligence and AI to discover new medicines for thousands of diseases that have no treatment

The healthcare industry is ripe for some major changes.  From chronic diseases and cancer to radiology and risk assessment, there are nearly endless opportunities to leverage technology to deploy more precise, efficient, and impactful interventions at exactly the right moment in a patient’s care. Artificial Intelligence offers a number of advantages over traditional analytics and clinical decision-making techniques. Learning algorithms can become more precise and accurate as they interact with training data, allowing humans to gain unprecedented insights into diagnostics, care processes, treatment variability, and patient outcomes.

Using computers to communicate is not a new idea by any means, but creating direct interfaces between technology and the human mind without the need for keyboards, mice, and monitors is a cutting-edge area of research that has significant applications for some patients. By powering a new generation of tools and systems that make clinicians more aware of nuances, more efficient when delivering care, and more likely to get ahead of developing problems, AI will usher in a new era of clinical quality and exciting breakthroughs in patient care.

BenevolentAI is the global leader in the development and application of artificial intelligence (AI) for scientific innovation. The firm aims to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases. Its team of technologists, AI researchers, and scientists builds and applies AI to the entire drug discovery and development process. The technology unlocks what is not known by creating new ideas based on established facts to provide a different understanding of disease, which leads to inventive steps and real insights that drive the development of new medicines and treatments.

Next-generation AI solutions offered by BenevolentAI for scientific innovation

The Benevolent Platform®: Built on powerful data foundations and state of the art technology, the Benevolent Platform® empowers scientists to decipher the vast and complex code underlying human biology and find new ways to treat disease. The knowledge graph is therapeutic area agnostic and data fabric enables powerful synergies across the entire drug discovery and development process.

Augmenting Knowledge and Reasoning: The firm’s knowledge pipeline pulls data from various structured and unstructured biomedical data sources and curates and standardizes this knowledge via a data fabric. This is fed into the proprietary knowledge graph which extracts and contextualizes the relevant information and is made up of a vast number of machine curated relationships between diseases, genes, drugs.

Novel Target Identification: Relation inference AI models help to predict potential disease targets that may be overlooked by scientists. BenevolentAI’s gene expression-based models help to identify proteins that are differentially expressed in healthy and diseased cells. This data-driven TargetID method increases hypothesis volume and also results in high quality target choices.

Patient specific treatments: Commonly, diseases have been defined by symptoms or location in the body, not by their underlying patient-specific molecular mechanisms or pathways. Its applied machine learning models enable scientists to determine the right mechanism to modulate, and identify patient endotypes most likely to respond to treatment.

Molecular Design: The chemical space for exploration is infinitely vast and only a small fraction of it can potentially be made into medicines. Its AI-augmented models empower chemists to evaluate millions of molecular structures, generate drug-like molecules, and design better drugs in fewer cycles.

BenevolentAI Drug Programmes: BenevolentAI has developed a growing pipeline of drug programmes extending from early discovery through to the clinic. The firm focuses in disease areas with high unmet medical need such as neurology, immunology, oncology, with ambition and capabilities to explore beyond.

The Marvel behind the glorious metamorphosis of BenevolentAI

Joanna Shields serves as the Chief Executive Officer of BenevolentAI. She is a tech industry veteran with over 25 years' experience building and scaling global companies, including Facebook, Bebo, Aol, Google, Real Networks, and Efi. Before joining BenevolentAI, she served in the UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and Chair and CEO of TechCityUK. Ms. Joanna is passionate about creating responsible technology that benefits humanity. She is a leading advocate for children's rights and safety online and founder of the WeProtect Global Alliance and a Life Peer of the House of Lords.

“Our mission is to re-engineer drug discovery and deliver life changing medicines for patients in need.”